Biolase Inc

Find Ratings Reports
BIOL : NASDAQ : Health Care
$1.71 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 69900.0
12/08/16 - 4:00 PM ET

Financial Analysis


BIOLASE INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. BIOLASE INC has average liquidity. Currently, the Quick Ratio is 1.39 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 1.07% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)13.2311.23
EBITDA ($mil)-2.86-5.09
EBIT ($mil)-3.15-5.35
Net Income ($mil)-3.15-5.34


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)12.915.39
Total Assets ($mil)44.6247.15
Total Debt ($mil)0.20.34
Equity ($mil)26.0626.34


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin44.5531.76
EBITDA Margin-21.61-45.28
Operating Margin-23.8-47.64
Sales Turnover1.181.0
Return on Assets-30.03-46.5
Return on Equity-55.61-83.22
Debt Q3 FY16 Q3 FY15
Current Ratio2.272.2
Debt/Capital0.010.01
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)67.5758.23
Div / share0.00.0
EPS-0.07-0.09
Book value / share0.390.45
Institutional Own % n/a n/a
Avg Daily Volume76804.085112.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 4.72 indicates a significant premium versus the S&P 500 average of 2.79 and a significant discount versus the industry average of 7.18. The price-to-sales ratio is above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BIOL NM Peers 55.01   BIOL NM Peers 21.93

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

BIOL's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BIOL's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BIOL NA Peers 22.36   BIOL NA Peers 0.85

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BIOL 4.72 Peers 7.18   BIOL 36.85 Peers 87.98

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BIOL is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BIOL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BIOL 2.34 Peers 6.09   BIOL 11.37 Peers 17.05

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BIOL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BIOL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades